reports
Aptevo Therapeutics Inc: 1 director
A director at Aptevo Therapeutics Inc bought 13,513 shares at 1.490USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...
Aptevo Therapeutics Receives Orphan Drug Designation for APVO436 for t...
Aptevo Therapeutics Receives Orphan Drug Designation for APVO436 for the Treatment of Acute Myelogenous Leukemia SEATTLE, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to APVO436, a bispecific antibody candidate intended for the treatment of acute myelogenous leukemia (AML). APVO436 is currently being evaluated in a Phase 1/1b clinical trial in patients with AML a...
Aptevo Therapeutics and Alligator Bioscience Present New Preclinical D...
Aptevo Therapeutics and Alligator Bioscience Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer 2019 Annual Meeting Preclinical Data Show That ALG.APV-527 is Well Tolerated with Repeated Dosing Preliminary in vivo Data Show that ALG.APV-527 has Potent Anti-tumor Activity and Induces an Immunological Memory Response SEATTLE and LUND, Sweden, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel immuno-oncology and hematology therapeutics and Alligator Bioscience AB (Nasdaq Stock...
Aptevo Therapeutics Reports Third Quarter 2019 Financial Results
Aptevo Therapeutics Reports Third Quarter 2019 Financial Results Reports Record Net Revenue for IXINITY; Achieves 55% Increase in Year-over-Year Quarterly Net Revenue Advances APVO436 Phase 1/1b Clinical Study in AML/MDS SEATTLE, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today provided a business review and reported its financial results for the third quarter ended September 30, 2019. “Net revenue for IXINITY® in the third quarter of 2019 reached a record level a...
Aptevo Therapeutics Provides Corporate and Pipeline Update
Aptevo Therapeutics Provides Corporate and Pipeline Update Reports Record Quarterly IXINITY® Net Revenue and New Patient Conversions Following Launch of New 3,000 IU Assay Provides Update on Ongoing APVO436 Phase 1/1b Clinical Study;Evidence of Potential Clinical Activity Emerging;No Dose-Limiting Toxicities or Anti-drug Antibodies Observed to Date in the Study Reports Decision to Discontinue Development of APVO210 Announces Expense Reduction Plan to Reduce Annual Cash Burn by Approximately 30% Management to Host Conference Call Today at 5:00 p.m. E.T./2:00 p.m. P.T. ...
Aptevo Therapeutics Introduces New Adaptirâ„¢ Bispecific Antibody Cand...
Aptevo Therapeutics Introduces New Adaptir™ Bispecific Antibody Candidate Intended for the Treatment of Solid Tumors New ADAPTIR Candidate APVO603 is a Dual-Agonistic BispecificAntibody Targeting 4-1BB and OX40 APVO603 is Designed to Induce Synergistic Effects on Immune Responseswith Potential to Enhance Anti-Tumor Immune Response Against Solid Tumors SEATTLE, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today introduced a new immuno-oncology candidate...
- Jonathan Moreland
GE GENERAL ELECTRIC COMPANY
WMGI WRIGHT MEDICAL GROUP NV
TXMD THERAPEUTICSMD INC.
SRPT SAREPTA THERAPEUTICS INC.
SPKE SPARK ENERGY INC-CLASS A
PFLT PENNANTPARK FLOATING RATE CAPITAL LTD.
PBF PBF ENERGY INC. CLASS A
NMFC NEW MOUNTAIN FINANCE CORPORATION
MTDR MATADOR RESOURCES COMPANY
MD MEDNAX INC.
LGND LIGAND PHARMACEUTICALS INCORPORATED
KRO KRONOS WORLDWIDE INC.
GTT GTT COMMUNICATIONS INC.
CRCM CARE.COM
AXGN AXOGEN INC.
MPLX MPLX LP
OW0A OCWEN FINANCIAL CORPORATION
UNVR UNIVAR SOLUTIONS INC.
RESN RESONANT INC
APVO APTEVO THERAPEUTICS
FRTA FORTERRA INC.
CNDT CONDUENT INC.
VNTR VENATOR MATERIALS PLC
CARS CARS.COM INC.
STKL SUNOPTA
GTES INC.
UPWK GATES INDUSTRIAL CORP
SCPL UPWORK
ENR SCIPLAY
EDGEWELL PERSONAL CARE COMPANY
Aptevo Therapeutics Reports Second Quarter 2019 Financial Results
Aptevo Therapeutics Reports Second Quarter 2019 Financial Results Reports Positive Preliminary Top-Line Safety Data for APVO210Phase 1 Single Ascending Dose (SAD) Clinical Study Advances APVO210 into Phase 1 Multiple Ascending Dose (MAD) Study Commences Dosing in Cohort 4 of APVO436 Phase 1 AML/MDS Clinical Trial Achieves 32% Increase in First Half 2019 Year-Over-Year IXINITY® Net Revenue;Launches New 3,000 IU IXINITY Assay for Enhanced IXINITY User Experience & Convenience Receives $4.3 Million Milestone Payment from Saol Therapeutics;Reconfirms $36-$40 Million 2019 Cash Burn ...
Aptevo Therapeutics Receives $4.3 Million Milestone Payment From Saol ...
Aptevo Therapeutics Receives $4.3 Million Milestone Payment From Saol International Limited Provides Additional Non-Dilutive Funding for Aptevo to Support the Achievement of Near-Term Clinical Milestones SEATTLE, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today the receipt of a $4.3 million milestone payment from Saol International Limited (Saol). This performance-based milestone has been collected more than one year earlier than anticipated in the original...
- Jonathan Moreland
MCHX MARCHEX INC. CL B
LB7 LIBBEY INC.
INUV INUVO INC
CSU CAPITAL SENIOR LIVING CORPORATION
COLL COLLEGIUM PHARMACEUTICAL INC.
VRML VERMILLION
CNFR CONIFER HOLDINGS
GIII G-III APPAREL GROUP LTD.
OTEL OTELCO INC
BXC BLUELINX HOLDINGS
APVO APTEVO THERAPEUTICS
SVRA SAVARA
FEIM FREQUENCY ELECTRONICS INC.
ACFN ACORN ENERGY
CTDH INC.
SLNO CTD HOLDINGS INC
HOG SOLENO THERAPEUTICS INC
MVBF HARLEY-DAVIDSON INC.
MOTS MVB FINANCIAL CORP
SLDB MOTUS GI HOLDINGS
EYEN SOLID BIOSCIENCES INC
ZUO EYENOVIA INC
CFBK ZUORA
CHAP CENTRAL FEDERAL CORP.
JILL CHAPARRAL ENERGY
KXIN INC.
EFF J.JILL
PBYI INC.
BW KAIXIN AUTO HOLDINGS (N SHARES)
EATON VANCE FLOATING-RATE INCOME PLUS FUND
INNOVATIVE ACQUISITIONS CORP
BABCOCK & WILCOX ENTERPRISES
- Jonathan Moreland
Aptevo Therapeutics Reports Continued Progress In APVO210 and APVO436...
Aptevo Therapeutics Reports Continued Progress In APVO210 and APVO436 Clinical Trials Completes Dosing in Single Ascending Dose (SAD) Phase 1 Study of APVO210 Receives Approval to Begin APVO210 Multiple Ascending Dose (MAD) Study Preliminary Data Suggest that Single Doses of APVO210 Appear to be Safe and Well Tolerated at Doses Equivalent to IL-10 Doses that Generated a Clinical Effectin Competitor IL-10 Clinical Studies No Anti-drug Antibodies Observed in APVO210 SAD Phase 1 StudyBased on Patient Samples Obtained to Date APVO436 Phase 1 Clinical Study Progressing on Track;Approval Rece...
- Jonathan Moreland
- Jonathan Moreland
- Jonathan Moreland
Aptevo Therapeutics Launches New 3000 IU IXINITY Assay Offering Enhanc...
Aptevo Therapeutics Launches New 3000 IU IXINITY Assay Offering Enhanced User Experience and Improved Convenience for Hemophilia B Patients Expands Options for Patients with Potential for Reduced Reconstitution Time and Infusion Volume SEATTLE, June 25, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today announced that it has launched a new, larger 3000 IU (international unit) vial size for IXINITY® [Coagulation Factor IX (Recombinant)] into the U.S. market. The...
- Jonathan Moreland
OXY OCCIDENTAL PETROLEUM CORPORATION
XNCR XENCOR INC.
TTSH TILE SHOP HOLDINGS INC.
TBK TRIUMPH BANCORP INC.
SIEN SIENTRA
SFLY SHUTTERFLY INC.
RRGB RED ROBIN GOURMET BURGERS INC.
OPK OPKO HEALTH INC.
OCUL OCULAR THERAPEUTIX
MTDR MATADOR RESOURCES COMPANY
MMLP MARTIN MIDSTREAM PARTNERS L.P.
LPTH LIGHTPATH TECHNOLOGIES INC. CL A
LGND LIGAND PHARMACEUTICALS INCORPORATED
IVZ INVESCO LTD.
HTBK HERITAGE COMMERCE CORP.
HEAR TURTLE BEACH CORP
ETM ENTERCOM COMMUNICATIONS CORP. CLASS A
ERIE ERIE INDEMNITY COMPANY CLASS A
ENT GLOBAL EAGLE ENTERTAINMENT INC
OVINTIV INC
DBD DIEBOLD NIXDORF INCORPORATED
CHFC TCF FINANCIAL CORPORATION
BUSE FIRST BUSEY CORPORATION
MTNB MATINAS BIOPHARMA HOLDINGS INC
CONN CONN'S INC.
CUB CUBIC CORPORATION
FTK FLOTEK INDUSTRIES INC.
HIL HILL INTERNATIONAL
MAC MACERICH COMPANY
MGM MGM RESORTS INTERNATIONAL
EHI WESTERN ASSET GLOBAL HIGH INCOME FUND
CC CHEMOURS CO.
OTEL OTELCO INC
CNBKA CENTURY BANCORP INC. CL A
LCUT LIFETIME BRANDS
HIO WESTERN ASSET HIGH INCOME OPPORTUNITY FUND
CWH CAMPING WORLD HOLDINGS INC. CLASS A
TPIC TPI COMPOSITES INC.
APVO APTEVO THERAPEUTICS
BTU PEABODY ENERGY CORPORATION
MYOV MYOVANT SCIENCE
NEPH NEPHROS INC
CLF CLIFFS NATURAL RESOURCES INC.
CTRA ALPHA METALLURGICAL RESOURCES INC.
ODT ODONATE THERAPEUTICS INC
CNX CONSOL ENERGY INC.
SFIX STITCH FIX CLASS A
EVFM EVOFEM BIOSCIENCES
REZI RESIDEO TECHNOLOGIES
AMEH INC.
TROX APOLLO MEDICAL HOLDINGS INC
CNR TRONOX HOLDINGS PLC
NWHM CORNERSTONE BUILDING BRANDS INC
CNCE THE NEW HOME COMPANY
COMMUNICARE CORP
- Jonathan Moreland
PRGX PRGX GLOBAL
OPK OPKO HEALTH INC.
HEAR TURTLE BEACH CORP
ETM ENTERCOM COMMUNICATIONS CORP. CLASS A
OVINTIV INC
CPST CAPSTONE TURBINE CORP.
CHFC TCF FINANCIAL CORPORATION
GES GUESS? INC.
TPL TEXAS PACIFIC LAND CORPORATION
PMD PSYCHEMEDICS CORP.
AGLE AEGLEA BIOTHERAPEUTICS
APVO APTEVO THERAPEUTICS
ELVT ELEVATE CREDIT
MYOV MYOVANT SCIENCE
NEPH NEPHROS INC
CTRA ALPHA METALLURGICAL RESOURCES INC.
ANGI ANGI INC. CLASS A
RBNC RELIANT BANCORP
AMEH APOLLO MEDICAL HOLDINGS INC
JWA JOHN WILEY & SONS
CNR INC.
CORNERSTONE BUILDING BRANDS INC
- Jonathan Moreland
TUESQ TUESDAY MORNING CORP.
TTSH TILE SHOP HOLDINGS INC.
STLD STEEL DYNAMICS INC.
REI RING ENERGY INC.
OPK OPKO HEALTH INC.
NTAP NETAPP INC.
4LT1 NORTHERN OIL & GAS INC.
MC MOELIS & CO. CLASS A
LTS LADENBURG THALMANN FINANCIAL SERVICES INC.
IEC IEC ELECTRONICS
HTBK HERITAGE COMMERCE CORP.
HIIQ HEALTH INSURANCE INNOVATIONS INC
GRPN GROUPON INC.
GALT GALECTIN THERAPEUTICS
OVINTIV INC
AKRX AKORN INC.
ADM ARCHER-DANIELS-MIDLAND COMPANY
AAL AMERICAN AIRLINES GROUP INC.
MLVF MALVERN BANCORP
HPR HIGH PEAK ROYALTIES
MTNB MATINAS BIOPHARMA HOLDINGS INC
CERC CERECOR INC
CONN CONN'S INC.
FI FRANK'S INTERNATIONAL NV
HIL HILL INTERNATIONAL
MGM MGM RESORTS INTERNATIONAL
HPE HEWLETT PACKARD ENTERPRISE CO.
EHI WESTERN ASSET GLOBAL HIGH INCOME FUND
TRC TEJON RANCH CO.
CNBKA CENTURY BANCORP INC. CL A
HIO WESTERN ASSET HIGH INCOME OPPORTUNITY FUND
X UNITED STATES STEEL CORPORATION
AMBC AMBAC FINANCIAL GROUP INC.
TPIC TPI COMPOSITES INC.
APVO APTEVO THERAPEUTICS
MYOV MYOVANT SCIENCE
NHF NEXPOINT CREDIT STRATEGIES FUN
TOCA TOCAGEN
CTRA ALPHA METALLURGICAL RESOURCES INC.
ANGI ANGI INC. CLASS A
ODT ODONATE THERAPEUTICS INC
STKL SUNOPTA
PTE INC.
DNLI POLARITYTE
RBB DENALI THERAPEUTICS INC
FUND RBB BANCORP
REZI ROYCE FOCUS TRUST
ENOB INC.
FSK RESIDEO TECHNOLOGIES
TROX INC.
INMB ENOCHIAN BIOSCIENCES INC
BSGM FS KKR CAPITAL CORP
CNR TRONOX HOLDINGS PLC
CPRI INMUNE BIO
NWHM INC.
SFLY BIOSIG TECHNOLOGIES INC.
CORNERSTONE BUILDING BRANDS INC
CAPRI NUSA SATU PROPERTI
THE NEW HOME COMPANY
SHUTTERFLY
INC.
- Jonathan Moreland
TUESQ TUESDAY MORNING CORP.
STLD STEEL DYNAMICS INC.
SPKE SPARK ENERGY INC-CLASS A
OPK OPKO HEALTH INC.
GRPN GROUPON INC.
GPRE GREEN PLAINS INC.
FRGI FIESTA RESTAURANT GROUP INC.
ENT GLOBAL EAGLE ENTERTAINMENT INC
CLR CONTINENTAL RESOURCES INC.
MLVF MALVERN BANCORP
MGM MGM RESORTS INTERNATIONAL
TPL TEXAS PACIFIC LAND CORPORATION
APVO APTEVO THERAPEUTICS
VC VISTEON CORP
ATNX ATHENEX
FSK FS KKR CAPITAL CORP
CNR CORNERSTONE BUILDING BRANDS INC
NWHM THE NEW HOME COMPANY
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.